Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome [clinicaltrials:NCT00065143]
Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome [clinicaltrials:NCT00065143]
Bio2RDF identifier
NCT00065143
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00065143
identifiers.org URI
actual enrollment [clinicaltrials_vocabulary:actual-enrollment]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
The goal of this clinic ...... eatment will also be studied.
brief title [clinicaltrials_vocabulary:brief-title]
Clofarabine Plus Cytarabine in ...... -risk Myelodysplastic Syndrome
collaborator [clinicaltrials_vocabulary:collaborator]
completion date [clinicaltrials_vocabulary:completion-date]
2006-02-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
The treatment of acute ...... atients with acute leukemias.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2003-07-17T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
is section 801 [clinicaltrials_vocabulary:is-section-801]
keyword [clinicaltrials_vocabulary:keyword]
Acute Myeloid Leukemia (AML)
High-risk myelodysplastic syndrome (MDS) (>/= 10% bone marrow blasts)
Myelodysplastic Syndrome (MDS)
Newly diagnosed and previously untreated acute myeloid leukemia (AML)
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2012-01-20T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00065143
official title [clinicaltrials_vocabulary:official-title]
A Phase II Study of Clofarabin ...... ) (>/= 10% Bone Marrow Blasts)
org study id [clinicaltrials_vocabulary:org-study-id]
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2006-02-01T00:00:00Z
responsible party [clinicaltrials_vocabulary:responsible-party]
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2003-06-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2012-01-01T00:00:00Z
identifier
clinicaltrials:NCT00065143
title
Clofarabine Plus Cytarabine in ...... -risk Myelodysplastic Syndrome
@en
type
label
Clofarabine Plus Cytarabine in ...... e [clinicaltrials:NCT00065143]
@en